What is Chardan Capital’s Estimate for EYPT FY2025 Earnings?

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Equities research analysts at Chardan Capital issued their FY2025 earnings per share estimates for EyePoint Pharmaceuticals in a research report issued on Monday, March 24th. Chardan Capital analyst D. Gataulin anticipates that the company will earn ($2.92) per share for the year. Chardan Capital currently has a “Buy” rating and a $33.00 target price on the stock. The consensus estimate for EyePoint Pharmaceuticals’ current full-year earnings is ($2.13) per share.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The business had revenue of $11.60 million during the quarter, compared to analysts’ expectations of $11.02 million.

A number of other analysts also recently weighed in on the stock. Citigroup initiated coverage on shares of EyePoint Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $33.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. Finally, StockNews.com raised EyePoint Pharmaceuticals to a “sell” rating in a research note on Friday, March 14th. One analyst has rated the stock with a sell rating and nine have given a buy rating to the stock. Based on data from MarketBeat, EyePoint Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $26.63.

EyePoint Pharmaceuticals Stock Down 1.4 %

NASDAQ EYPT opened at $5.83 on Thursday. EyePoint Pharmaceuticals has a twelve month low of $5.54 and a twelve month high of $23.65. The business has a 50-day moving average price of $6.79 and a 200-day moving average price of $8.23. The firm has a market cap of $400.69 million, a price-to-earnings ratio of -2.92 and a beta of 1.41.

Institutional Investors Weigh In On EyePoint Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Intech Investment Management LLC purchased a new position in shares of EyePoint Pharmaceuticals in the third quarter valued at approximately $136,000. Charles Schwab Investment Management Inc. boosted its stake in EyePoint Pharmaceuticals by 5.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 142,763 shares of the company’s stock worth $1,141,000 after purchasing an additional 7,967 shares during the last quarter. Patient Square Capital LP purchased a new stake in shares of EyePoint Pharmaceuticals during the third quarter worth $10,882,000. Wellington Management Group LLP raised its position in shares of EyePoint Pharmaceuticals by 59.4% in the third quarter. Wellington Management Group LLP now owns 171,764 shares of the company’s stock valued at $1,372,000 after buying an additional 64,008 shares during the last quarter. Finally, Barclays PLC lifted its stake in shares of EyePoint Pharmaceuticals by 410.4% in the third quarter. Barclays PLC now owns 245,045 shares of the company’s stock worth $1,959,000 after buying an additional 197,033 shares in the last quarter. Institutional investors and hedge funds own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.